Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Socialization of Adult Men With Congenital Hemophilia A or B
Socialization of Adult Men With Congenital Hemophilia A or B: A Study to Examine Socialization Measures, the Role of Spouse/Significant Other and Health Related Quality of Life
Status: Enrolling
Updated:  1/13/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Socialization of Adult Men With Congenital Hemophilia A or B
Socialization of Adult Men With Congenital Hemophilia A or B: A Study to Examine Socialization Measures, the Role of Spouse/Significant Other and Health Related Quality of Life
Status: Enrolling
Updated: 1/13/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase II Trial of CLAG-M in Relapsed ALL
Status: Enrolling
Updated:  1/19/2012
Westchester Medical Center/New York Medical College
mi
from
Valhalla, NY
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase II Trial of CLAG-M in Relapsed ALL
Status: Enrolling
Updated: 1/19/2012
Westchester Medical Center/New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Non-invasive Quantification of Liver Iron With MRI
Non-invasive Quantification of Liver Iron With MRI
Status: Enrolling
Updated:  1/19/2012
Wisconsin Institutes for Medical Research
mi
from
Madison, WI
Non-invasive Quantification of Liver Iron With MRI
Non-invasive Quantification of Liver Iron With MRI
Status: Enrolling
Updated: 1/19/2012
Wisconsin Institutes for Medical Research
mi
from
Madison, WI
Click here to add this to my saved trials
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated:  2/3/2012
Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program
mi
from
Boston, MA
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated: 2/3/2012
Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program
mi
from
Boston, MA
Click here to add this to my saved trials
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated:  2/3/2012
Massachusetts General Hospital
mi
from
Boston, MA
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated: 2/3/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated:  2/3/2012
Ohio State Univeristy Comprehensive Cancer Center
mi
from
Columbus, OH
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated: 2/3/2012
Ohio State Univeristy Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Status: Enrolling
Updated:  2/9/2012
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Status: Enrolling
Updated: 2/9/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Status: Enrolling
Updated:  2/21/2012
Virginia Commonwealth University Health System
mi
from
Richmond, VA
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Status: Enrolling
Updated: 2/21/2012
Virginia Commonwealth University Health System
mi
from
Richmond, VA
Click here to add this to my saved trials
Treatment Study Topical NSAID, PENNSAID and Effect on Coagulation Values in Patients With Osteoarthritis Knee Pain Taking Warfarin
Single Center, Open-label Study of Effect of PENNSAID (Diclofenac Sodium Solution Topical) on Coagulation Parameters (PT, PTT, and INR) in Patients With Moderate to Severe Osteoarthritis Pain of the Knee Taking Anticoagulant Medication
Status: Enrolling
Updated:  2/23/2012
Arthritis Treatment Center
mi
from
Frederick, MD
Treatment Study Topical NSAID, PENNSAID and Effect on Coagulation Values in Patients With Osteoarthritis Knee Pain Taking Warfarin
Single Center, Open-label Study of Effect of PENNSAID (Diclofenac Sodium Solution Topical) on Coagulation Parameters (PT, PTT, and INR) in Patients With Moderate to Severe Osteoarthritis Pain of the Knee Taking Anticoagulant Medication
Status: Enrolling
Updated: 2/23/2012
Arthritis Treatment Center
mi
from
Frederick, MD
Click here to add this to my saved trials
Study of EB10 in Patients With Leukemia
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/24/2012
ImClone Investigational Site
mi
from
Columbus, OH
Study of EB10 in Patients With Leukemia
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/24/2012
ImClone Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of EB10 in Patients With Leukemia
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/24/2012
ImClone Investigational Site
mi
from
Houston, TX
Study of EB10 in Patients With Leukemia
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/24/2012
ImClone Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity
Status: Enrolling
Updated:  3/2/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity
Status: Enrolling
Updated: 3/2/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated:  3/16/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated: 3/16/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated:  3/16/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML
Status: Enrolling
Updated: 3/16/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
Status: Enrolling
Updated:  3/21/2012
Oregon Health and Science University
mi
from
Portland, OR
Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
Status: Enrolling
Updated: 3/21/2012
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Open Label Use Of RiaStap During Aortic Reconstruction
Open Label Use Of RiaStap During Aortic Reconstruction
Status: Enrolling
Updated:  3/27/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Open Label Use Of RiaStap During Aortic Reconstruction
Open Label Use Of RiaStap During Aortic Reconstruction
Status: Enrolling
Updated: 3/27/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Sutter East Bay Hospitals
mi
from
Berkley, CA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Sutter East Bay Hospitals
mi
from
Berkley, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
MCG Cancer Center
mi
from
Augusta, GA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
MCG Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Kansas University Medical Center
mi
from
Kansas City, KA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
University of Kentucky Markey Cancer Center Clinical Research Organization
mi
from
Lexington, KY
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
University of Kentucky Markey Cancer Center Clinical Research Organization
mi
from
Lexington, KY
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Montefiore Medical Center
mi
from
Bronx, NY
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Mid Dakota Clinical P.C. - Cancer Treatment and Research Center
mi
from
Bismarck, ND
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Mid Dakota Clinical P.C. - Cancer Treatment and Research Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Gabrail Cancer Center
mi
from
Canton, OH
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Pharma Resource
mi
from
East Providence, RI
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Pharma Resource
mi
from
East Providence, RI
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated:  4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated: 4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated:  4/10/2012
Baylor College of Medicine
mi
from
Houston, TX
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated: 4/10/2012
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura
Phase II Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in The Prevention and Treatment of Senile Purpura
Status: Enrolling
Updated:  4/19/2012
Multispecialty Aesthetic Clinical Research Organization
mi
from
Woodland Hills, CA
A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura
Phase II Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in The Prevention and Treatment of Senile Purpura
Status: Enrolling
Updated: 4/19/2012
Multispecialty Aesthetic Clinical Research Organization
mi
from
Woodland Hills, CA
Click here to add this to my saved trials
A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura
Phase II Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in The Prevention and Treatment of Senile Purpura
Status: Enrolling
Updated:  4/19/2012
Multispecialty Aesthetic Clinical Research Organization
mi
from
Woodland Hills, CA
A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura
Phase II Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in The Prevention and Treatment of Senile Purpura
Status: Enrolling
Updated: 4/19/2012
Multispecialty Aesthetic Clinical Research Organization
mi
from
Woodland Hills, CA
Click here to add this to my saved trials
Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT
A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  4/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT
A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 4/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Trial of TBL-12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
A Phase II Trial of TBL-12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
Status: Enrolling
Updated:  5/2/2012
New York University School of Medicine, Clinical Cancer Center
mi
from
New York, NY
A Trial of TBL-12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
A Phase II Trial of TBL-12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
Status: Enrolling
Updated: 5/2/2012
New York University School of Medicine, Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  5/11/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 5/11/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated:  5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated: 5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  5/15/2012
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 5/15/2012
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  5/15/2012
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 5/15/2012
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
A Pilot Study of Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/17/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
A Pilot Study of Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/17/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing
Effects of HBOT for Edema/Ecchymosis After Upper Eyelid Blepharoplasty (Single Site Study)
Status: Enrolling
Updated:  5/22/2012
Restorix Research Institute
mi
from
Issaquah, WA
Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing
Effects of HBOT for Edema/Ecchymosis After Upper Eyelid Blepharoplasty (Single Site Study)
Status: Enrolling
Updated: 5/22/2012
Restorix Research Institute
mi
from
Issaquah, WA
Click here to add this to my saved trials
A Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Status: Enrolling
Updated:  5/29/2012
Tufts Medical Center
mi
from
Boston, MA
A Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Status: Enrolling
Updated: 5/29/2012
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg®) as for Treatment of Patients With CD33-Positive Acute Myeloid Leukemia (AML)
Status: Archived
Updated:  5/29/2012
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg®) as for Treatment of Patients With CD33-Positive Acute Myeloid Leukemia (AML)
Status: Archived
Updated: 5/29/2012
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
University of Southern California
mi
from
Los Angeles, CA
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Comprehensive Cancer Center of the Desert
mi
from
Palm Springs, CA
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Comprehensive Cancer Center of the Desert
mi
from
Palm Springs, CA
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Weill Medical College
mi
from
New York, NY
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Weill Medical College
mi
from
New York, NY
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Duke Univ Med Ctr
mi
from
Durham, NC
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials